Outsourced microbiological support to hospital-based surveillance of CDI aims to increase the capacity of laboratories in EU/EEA Member States to perform diagnostic practices with high diagnostic accuracy and acquire comparable typing data from C. difficile isolates.
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
For 2021, the 30 countries in the European Union/European Economic Area (EU/EEA) reported a total of 33 527 tuberculosis (TB) cases (7.4 per 100 000 population).
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
In 2019, 8 874 (7.4%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection, or urinary tract infection).
Between 2018 and 2020, nearly 20 000 surgical site infections (SSIs) were reported from a total of over 1.2 million surgical procedures in 13 EU/EEA countries participating in ECDC-coordinated SSI surveillance. Over 2 500 hospitals are part of this surveillance network.
In 2018, 9 860 (7.8%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection or urinary tract infection).